Palsdottir T, et al. - In this prospective cohort study, researchers determined the effect of different prostate-specific antigen (PSA), widely used to screen for prostate cancer, testing intervals on Gleason score [GS] at diagnosis and the risk of experiencing false-positive biopsy recommendations. Between 2003 and 2015, 174,636 men (aged 50-74 years) with at least two PSA tests were included. Investigators found that men (aged 50–74 years) with PSA ≤1 ng/mL can wait 3–4 years before a new PSA test is performed. They observed an increased risk for men with PSA >1 ng/mL of being diagnosed with GS ≥7 prostate cancer with longer than annual testing intervals. This benefit must be balanced against the significantly increased risks with recommendations for false-positive biopsy with shorter test intervals.